The present invention describes methods for inhibition angiogenesis in tissues using vitronectin .alpha..sub.v.beta..sub.3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing .alpha..sub.v.beta..sub.3 antagonists.